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of HCV infection which exerts a chronic stimulus to 
the immune system, facilitating clonal B-lymphocyte 
expansion and consequent wide autoantibody produc-
tion, including cryo- and non-cryo-precipitable immune 
complexes which may lead to organ- and non-organ-
specific immunological alterations. This review outlines 
the principal aspects of such HCV-induced immunologi-
cal alterations, focusing on the prevalence of these 
less characterized HCV extrahepatic manifestations.
Calvaruso V, Craxì A. Immunological alterations in hepatitis C 
virus infection. World J Gastroenterol 2013; 19(47): 0000-0000 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v19/i47/0000.htm  DOI: http://dx.doi.org/10.3748/wjg.v19.
i47.0000
INTRODUCTION
Autoimmunity and viral infections are closely related, 
and the hepatitis C virus (HCV), is recognized as one 
of  the viruses most often associated with autoimmune 
features. For this reason HCV is not only associated 
with chronic hepatic inflammation but also an array of  
extrahepatic complications. In the majority of  these as-
sociated extrahepatic manifestations, the pathogenic 
mechanism appears to be immunologically driven, with 
many having features of  autoimmunity. HCV infection 
has been associated with both organ-specific [thyroid-
itis, diabetes, autoimmune hepatitis (AIH)] and systemic 
autoimmune diseases and this association has generated 
growing interest in recent years since it is often observed 
in patients with chronic HCV infection. 
PATHOGENESIS OF HCV RELATED IM-
MUNE DISORDERS 
HCV lymphotropism represents the most relevant step 
in the pathogenesis of  virus-related immunological dis-
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Abstract
A higher prevalence of immunological processes has 
recently been reported in patients with hepatitis C virus 
(HCV) infection, focusing the attention of physicians 
and researchers on the close association between HCV 
and immune disorders. HCV lymphotropism represents 
the most important step in the pathogenesis of virus-
related immunological diseases and experimental, viro-
logic, and clinical evidence has demonstrated a trigger 
role for HCV both in systemic autoimmune diseases, 
such as rheumatoid arthritis, Sjögren syndrome, he-
molytic anemia and severe thrombocytopenia, and in 
organ-specific autoimmune diseases, such as autoim-
mune hepatitis, thyroid disorders and diabetes. This 
review will outline the principal aspects of such HCV-
induced immunological alterations, focusing on the 
prevalence of these less characterized HCV extrahe-
patic manifestations. 
© 2013 Baishideng �ublishing Group Co., Limited. All rights 
reserved.
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Core tip: Hepatitis C virus (HCV)-infected lymphoid tis-
sue of the host represents a site for the persistence 
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orders[1]. Indeed, infected lymphoid tissue of  the host 
represents a site for the persistence of  the HCV infec-
tion[2-6]. HCV exerts a chronic stimulus to the immune 
system, facilitating the clonal B-lymphocyte expansion 
and consequent wide autoantibody production, including 
cryo- and non-cryoprecipitable immune complexes[3,7-9] 
which may lead to organ- and non-organ-specific immu-
nological alterations[3,7,8,10]. The first step is translocation, 
demonstrated in a high percentage of  HCV-infected pa-
tients, with consequent Bcl-2 proto-oncogene activation, 
antiapoptotic activity and prolonged survival of  lympho-
cytes[3,7,9,10]. Besides, the identification of  HCV envelope 
protein E2 able to bind the CD81 molecule expressed 
on both hepatocytes and B-lymphocytes seems to be 
crucial for HCV-driven autoimmunity[3,7,9,10]. 
Dysregulation of  cytokine networks skewing regula-
tory T-cells to a Th2 phenotype, which may be associ-
ated with enhanced humoral immune responses and 
autoantibody production has also been related to the ex-
pansion of  autoantibody-producing B-cells and chronic 
lymphoproliferation in HCV infection[11]. HCV infec-
tions induce a massive chemokine and cytokine burst 
and therefore recruit leukocytes to the site of  infection 
with the goal to stop viral spread. This excitation of  the 
human defense system could stimulate a potentially self-
reactive lymphocytes inducing autoimmunity in suscep-
tible individuals[11]. 
Many studies have linked Th1 immune response with 
HCV infection[12], mixed cryoglobulinemia (MC)[13] and 
organ specific autoimmune disorders[14]. These findings 
suggest that a possible common immunological Th1 pat-
tern could be the pathophysiological base of  the associa-
tion of  autoimmunity related HCV infections. 
Several studies have shown an increased expression 
of  interferon-gamma (IFN-γ), and IFN-γ inducible 
chemokines (C-X-C motif  chemokine 10 - CXCL10), 
in hepatocytes and in lymphocytes of  HCV-infected 
patients[12,15,16], which are directly related to the degree 
of  inflammation and an increase in circulating levels of  
IFN-γ and CXCL10[17,18]. 
Furthermore, it has been shown that NS5A and core 
proteins, alone or by a synergistic effect with Th1 cyto-
kines [IFN-γ and tumor necrosis factor-α (TNF-α)], are 
capable of  upregulating CXCL10 and monokine induced 
by gamma interferon (MIG) gene expression and secre-
tion in cultured human hepatocyte derived cells. These 
data suggest that CXCL10 produced by HCV-infected 
hepatocytes could play a key role regulating T-cell traf-
ficking into a Th1-type inflammatory site by recruiting 
Th1 lymphocytes, that secrete IFN-γ and TNF-α, with a 
synergistic effect on CXCL10 secretion by hepatocytes, 
thus perpetuating the immune cascade[19].
HCV AND SYSTEMIC AUTOIMMUNE DIS-
EASES 
Mixed cryoglobulinemia 
MC is the most well documented extrahepatic manifesta-
tion of  HCV infection[2,20]. MC, which is defined by doc-
umenting cryoprecipitates in serum (Ig precipitates from 
serum at temperatures under 37 ℃ and dissolves upon 
re-warming), is characterized by the presence of  circulat-
ing immunocomplexes produced by a benign prolifera-
tion of  B-cells. MC represents the link between HCV 
and various autoimmune and lymphoproliferative disor-
ders. Although serum cryoglobulins (CGs) are frequently 
present in patients with chronic HCV[3-5,21,22], in many 
of  them CGs are present at low levels and symptoms 
are often absent or very mild. Only about 5% of  HCV-
infected subjects have clinically overt MC syndrome. 
HCV-related arthritis
Chronic oligo-polyarthritis during chronic HCV infec-
tion is often associated with MC but can also represent 
an independent entity. Indeed, it is not rare to observe a 
simple association between HCV infection and classical 
rheumatoid arthritis (RA) that can co-exist by chance or 
can be related to the ability of  HCV to act as a trigger 
of  the immune disease in individuals genetically predis-
posed to RA. 
A polyarthritis, which is often non-erosive and rarely 
progressive, and involves small joints is the most com-
mon kind of  arthritis associated with HCV chronic 
infection without the coexistence of  cryoglobulinemia. 
Instead, 40%-80% of  HCV-infected patients with MC[23] 
are reported to have a bilateral and symmetric arthralgia, 
which is non-deforming and includes mainly the knees 
and hands, and, more seldom, the elbows and ankles. 
Rheumatoid factor (RF) activity is found in 70%-80% 
of  MC patients but is not correlated with the presence 
of  articular disease, as patients chronically infected with 
HCV in the absence of  HCV-MC or RF may have prom-
inent articular symptoms. Usually there is no evidence 
of  joint destruction, and antibodies to cyclic citrullinated 
peptide, which are highly specific to rheumatoid arthritis, 
are absent[24]. These evidences suggest that HCV infec-
tion should be considered in the differential diagnosis of  
patients with atypical arthritis.
Sjögren syndrome
Another autoimmune condition associated with HCV 
is a chronic lymphocytic sialoadenitis similar to siaload-
enitis associated with idiopathic Sjögren syndrome (SS), 
which has been reported in approximately 50% of  pa-
tients with HCV infection[25]. 
Some authors have distinguished the HCV-related 
sicca syndrome from Sjogren’s syndrome based on several 
differences, including absence of  anti-SSA and anti-SSB 
antibodies, pericapillary and non pericanalary lympho-
cytic infiltration, lack of  glandular canal damage, high 
prevalence of  mixed cryoglobulinemia (50%), hypo-
complementemia (51%), and systemic vasculitic mani-
festations (58%)[25-28]. Moreover, the lymphocytic type 
of  the infiltrate in the minor salivary gland shows a pre-
dominance of  CD8 lymphocytes which is not observed 
in primary SS[29]. Although the possible etiopathogenetic 
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role of  HCV in SS remains a controversial issue[27], the 
explanation for this extrahepatic manifestation could be 
a cross reactivity between the HCV envelope and host 
salivary tissue which lead to an immune reaction directed 
against salivary glands[26]. The correct classification of  
patients with sialoadenitis related to HCV chronic infec-
tion have important clinical, prognostic and therapeutic 
implications since it may evolve into a B cell malignant 
lymphoma, especially in the presence of  MC[10,30].
HCV related cardiac disorders
Several observations suggest that HCV infection is an 
important cause of  a variety of  otherwise unexplained 
heart diseases. Indeed, it was reported that (+) or (-) 
chain HCV-RNAs can be detected in the biopsied myo-
cardial tissue or in the autopsied heart suggesting that 
HCV might proliferate in the myocardium[31], resulting in 
induction of  cardiomyopathy. Frustaci et al[32] have shown 
that HCV replicates in myocardial tissue of  patients 
with myocarditis, and that HCV infection may contrib-
ute to the development of  an autoimmune myocarditis, 
frequently associated with myocardial antibodies and 
responsive to immunosuppressive therapy. In 2000, Mat-
sumori suggested that some specific HCV clones with 
high affinity for the heart can develop and cause cardio-
myopathy[33] and in 2006, in a large study involving more 
than 1000 patients, the same group identified anti-HCV 
antibodies, HCV RNA, NT-proBNP, and cardiac tropo-
nin I and T in sera stored for up to 17 years, and found 
the anti-HCV antibodies were more prevalent in patients 
with myocarditis than in the general US population[34]. 
These results suggest that in regions where its preva-
lence is high, HCV infection may be an important cause 
of  myocarditis and heart failure. Moreover, the same 
authors concluded that NT-proBNP is a more sensitive 
marker of  myocardial injury than cardiac troponins in 
patients with heart failure from HCV myocarditis. More 
recently, other studies confirmed that NT-proBNP is a 
sensitive biomarker for identifying patients with heart 
failure caused by HCV-related myocarditis[35,36]. Antonelli 
et al[36] assessed serum NTproBNP in 50 HCV-positive 
patients and in 50 sex- and age-matched controls. HCV 
patients showed significantly higher mean NT-proBNP 
level than controls[35]. This result was confirmed by the 
same group in another study where TNF-α was also 
found to be higher in HCV+ patients with respect to 
controls, suggesting the presence of  subclinical cardiac 
dysfunction[36]. 
AUTOIMMUNE CYTOPENIAS IN PATIENT 
WITH HCV INFECTION
Hemolytic anemia and severe thrombocytopenia were the 
most frequent cytopenias observed in patients with HCV 
infection. The different types of  immune-mediated cyto-
penias may be severe and clinically significant.
Hemolytic anemia
Although autoimmune hemolytic anemia (AHA) has fre-
quently been reported in association with HCV in the set-
ting of  interferon (IFN) treatment[37,38], it has also been 
observed as an isolated extrahepatic manifestation. The 
existence of  AHA in patients with chronic hepatitis was 
first described in 1951, when Hyman et al[39] described 
AHA in 3 patients with chronic liver involvement. In 
1973, Panush et al[40] described a patient with chronic ac-
tive hepatitis who presented with AHA with a positive 
Coombs test, who responded to treatment with steroids. 
In 1982, Portell et al[41] reported 5 patients with chronic 
hepatopathy (3 with active chronic hepatitis and 2 with 
cirrhosis) and a positive Coombs AHA, with positive 
ANA in 4 and sicca syndrome in 1. In 2001, 2 cases of 
HCV infection associated with Coombs-positive AHA, 
in the absence of  treatment with IFN, were reported 
by Srinivasan[42] and Chao et al[43], respectively. In 2003, 
Ramos-Casals et al[44] presented the largest series of  cases 
of  HCV-related AHA not treated with antiviral therapy. 
Seventeen HCV patients, mostly women with a mean age 
of  56 years, presented a high level of  association with 
autoimmune diseases, with cryoglobulinemia as the most 
frequent immunologic marker. Most patients had a history 
of  liver cirrhosis and even if  they had a good response to 
corticosteroids, the prognosis was poor (56% mortality).
HCV-associated immune thrombocytopenic purpura
Although thrombocytopenia during the course of  chron-
ic liver disease is usually attributed to hypersplenism, an 
autoimmune mechanism has been suggested as playing a 
role in some patients with HCV infection. This hypoth-
esis is based on the observation of  a greater prevalence 
of  thrombocytopenia and antiplatelet antibodies in HCV 
patients compared with HBV patients[45], and of  the fre-
quency of  HCV infection seen among patients initially 
diagnosed with idiopathic thrombocytopenic purpura 
(ITP)[46-48]. The pathophysiology of  infection-related ITP 
involves diverse immunologic pathways as well as non-
immune mechanisms that accelerate platelet destruction 
and/or decrease platelet production.
High affinity binding of  HCV to the platelet mem-
brane with subsequent binding of  anti-HCV antibody 
might lead to phagocytosis of  platelets[49]. Dysregulation 
of  the host immune system triggering the production 
of  autoantibodies against platelet glycoproteins has also 
been postulated[45,50]. However there have been conflict-
ing data on the presence of  specific antibodies in plate-
lets in patients with HCV-related ITP[45,50-52]. 
Thrombocytopenia in HCV patients may be present 
even in the absence of  clinically evident liver disease or 
splenomegaly and may be mistakenly diagnosed as prima-
ry chronic immune thrombocytopenic purpura (CITP)[48,53]. 
Six cross-sectional studies have reported serologic evi-
dence of  HCV infection in 20% of  patients with a clinical 
diagnosis of  CITP[48,53-57], and in the largest series pub-
lished to date, HCV antibodies were identified in 30% of  
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250 patients fulfilling the American Society of  Hematol-
ogy criteria for CITP[54]. There were significant differences 
in the demographic characteristics of  patients with HCV-
positive compared with patients with HCV-negative CITP. 
Patients positive for HCV were older and the incidence 
was distributed equally between the sexes compared with 
the female predominance in HCV-negative CITP.
ORGAN-SPECIFIC AUTOIMMUNE DIS-
EASES
Thyroid disorders and HCV
Autoimmune thyroid involvement and hypothyroidism 
were significantly more frequent in patients with chronic 
hepatitis C (CHC) than in comparison groups such as 
patients with viral hepatitis B or D[58-60] or normal sub-
jects[61,62]. The most frequent thyroid disorder in this set-
ting is the presence of  circulating anti-thyroid antibodies 
which is more commonly reported in female subjects[58]. 
The prevalence of  abnormally high levels of  anti-thyroid 
antibodies observed in these patients ranges from 2% 
to 48%[58,61,63,64], with heterogeneous geographic distribu-
tion[65]. These discrepancies are related to variable genet-
ic predisposition and environmental co-factors, such as 
iodine intake or other infectious agents[66]. The evidence 
of  a subclinical hypothyroidism was observed in 2%-9% 
of  patients with chronic HCV infection, particularly 
in those patients with MC[59,60,62,63,67], and these patients 
seem to be susceptible to Hashimoto’s autoimmune thy-
roiditis and Grave’s disease when treated with interferon. 
Antonelli et al[21] in 2004 analyzed 630 consecutive 
patients affected by CHC compared with a large control 
group of  subjects from iodine-deficient and sufficient 
areas and with 86 patients with chronic hepatitis B. They 
demonstrated that patients with CHC were more likely 
to have hypothyroidism, anti-thyroglobulin and anti-thy-
roid peroxidase antibodies than any of  the other groups. 
The same group evaluated thyroid function, the presence 
of  thyroid autoantibodies, thyroid nodules and thyroid 
cancer, in 93 HCV + MC consecutive patients matched 
by sex and age to 93 patients with CHC without MC and 
93 healthy (HCV-negative) controls. Subclinical hypo-
thyroidism and thyroid autoimmunity were significantly 
more frequent in HCV + MC patients than in HCV-
negative controls. Moreover, serum thyroid peroxidase 
antibodies were also significantly more frequent in HCV 
+ MC patients than in CHC patients. Finally, the preva-
lence of  thyroid nodules was not significantly different 
in the three groups[68]. In conclusion, pooling all data 
about HCV-positive patients (with CHC or HCVAb pos-
itivity) and using as control healthy subjects and HBV-
infected patients, there was a significant increase in the 
prevalence of  both thyroid autoimmune disorders (OR 
= 1.6; 95%CI: 1.4-1.9] and hypothyroidism (OR = 2.9; 
95%CI: 2.0-4.1)[69].
Some authors have reported that patients with chronic 
HCV have a higher prevalence of  papillary thyroid car-
cinoma[70,71]. In 2002, the prevalence of  thyroid cancer in 
a series of  94 HCV-related mixed cryoglobulinemic pa-
tients was investigated[70]. A control group was obtained 
from a sample of  the general population (2401 subjects) 
who had undergone thyroid ultrasonography. The preva-
lence of  thyroid nodules was higher, although not signif-
icantly so, in control subjects than in MC patients but 2 
patients with papillary thyroid cancer were found in the 
MC series, while no case was observed among controls. 
A more recent study[71] prospectively investigated the 
prevalence and features of  thyroid cancer in 308 patients 
with CHC in comparison with 2 large sex- and age-
matched control groups from the general population with 
different iodine intake. Thyroid status was assessed by 
measurement of  circulating thyroid hormones and auto-
antibodies, thyroid ultrasonography, and, when indicated, 
fine-needle aspiration cytology. The authors have found 
that circulating thyrotropin, anti-thyroglobulin, and anti-
thyroperoxidase antibodies levels, and the prevalence of  
hypothyroidism were significantly higher in HCV patients 
and 6 cases of  papillary thyroid cancer were detected 
among HCV patients, whereas only 1 case was observed 
in controls, suggesting a high prevalence of  thyroid papil-
lary cancer in HCV patients. Because of  this high preva-
lence of  thyroid disorders, the guidelines on management 
of  CHC recommend investigation of  thyroid function, 
including free T4 and TSH in all patients, and since inter-
feron-based therapy could exacerbate thyroid dysfunction, 
thyroid function tests should be fully evaluated prior to 
initiating HCV treatment. 
Diabetes mellitus and HCV
Data from the literature have shown a higher incidence 
of  type 2 diabetes mellitus with chronic HCV when 
compared with patients with other liver disorders[72-74]. 
In a large study[75] involving 229 consecutively recruited 
MC-HCV patients compared with 217 sex- and age-
matched controls without HCV infection, the prevalence 
of  type 2 diabetes was significantly higher in MC-HCV 
patients than in controls. Moreover, MC-HCV diabetic 
patients more often had non-organ-specific autoantibod-
ies than non-diabetic MC-HCV patients.
Another study conducted in 2005 by the same group[22], 
established the prevalence and clinical phenotype of  
type 2 diabetes in a large series of  non-cirrhotic HCV 
patients. The prevalence of  type 2 diabetes was signifi-
cantly higher in HCV patients compared with control 
subjects or non-cirrhotic HBV patients. Moreover, type 
2 diabetic HCV patients had a significantly lower BMI 
than type 2 diabetic control subjects and significantly 
higher BMI than non-diabetic HCV patients. In contrast, 
no association with diabetes mellitus type 1 has been 
identified[22,72,73,76-78]. The association between chronic 
HCV and diabetes mellitus seems to be independent of  
the severity of  the liver disease and is associated with in-
sulin-resistance, but not with the presence of  pancreatic 
anti-insulin antibodies[79]. In contrast, interferon treat-
ment of  HCV has been associated with the appearance 
of  diabetes mellitus type 1 and development of  anti-
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pancreas autoimmunity[80-82].
AIH and HCV infection
Finally, an intriguing, still controversial aspect is the pos-
sible etiopathogenetic role of  HCV in AIH[3,6,8,9,65]. Pa-
tients with AIH may present with mixed cryoglobulins, 
HCV infection, and extrahepatic manifestations such as 
thyroiditis, sicca syndrome, and arthritis[6], while patients 
with HCV infection show one or more non-organ-spe-
cific auto-antibodies. The antigenic target specificity of  
HCV-related autoantibodies shows only quantitative dif-
ferences compared with those associated with “primary” 
AIH[8]. 
In clinical practice, the search for serum autoantibod-
ies should be limited to cases for whom treatment with 
IFN is planned. An exception may be cases where clini-
cal data (female gender, young age), high biochemical 
activity (transaminase-globulins) and histological aspects 
(interfaces hepatitis) of  liver disease may suggest the 
presence of  AIH with superimposed HCV infection. 
The heterogeneous geographical distribution of  HCV-
associated AIH[65] suggests a possible involvement of  
various pathogenetic co-factors; among these, HCV might 
trigger a particular AIH clinico-serological subset, which 
is prevalent in specific geographical areas.
CONCLUSION
In the case of  patients with chronic HCV infection, the 
possible existence of  extrahepatic manifestations should 
be taken into account and an accurate analysis of  clini-
cal and anamnestic data is recommended. Some patients 
may display the entire complex spectrum of  HCV-
related disorders which could be mild for many years 
and progress, generally during a long follow-up, to more 
severe systemic manifestations. In the last few years, very 
consistent data have been accumulated through different 
in vivo and in vitro models, suggesting that a more accu-
rate characterization of  the modalities and consequences 
at the molecular level of  HCV infection of  lymphatic 
cells may be of  great importance in the future for the 
clarification of  the pathogenesis of  several pathological 
manifestations of  HCV. 
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